Objective: To examine the pricing trajectories in the United States of disease-modifying therapies (DMT) for multiple sclerosis (MS) over the last 20 years and assess the influences on rising prices.
Methods: We estimated the trend in annual drug costs for 9 DMTs using published drug pricing data from 1993 to...
Objective: To examine the pricing trajectories in the United States of disease-modifying therapies (DMT) for multiple sclerosis (MS) over the last 20 years and assess the influences on rising prices.
Methods: We estimated the trend in annual drug costs for 9 DMTs using published drug pricing data from 1993 to...
Full Text:
toward a cure for MS is hampered because
it would affect profits.
Author Response: Daniel M. Hartung
Objective: To examine the pricing trajectories in the United States of disease-modifying therapies (DMT) for multiple sclerosis (MS) over the last 20 years and assess the influences on rising prices.
Methods: We estimated the trend in annual drug costs for 9 DMTs using published drug pricing data from 1993 to...
Full Text:
ISSUES
Daniel M. Hartung,
PharmD, MPH
Dennis N. Bourdette,
MD
Sharia M. Ahmed, MPH
Ruth H. Whitham, MD
Objective: To examine the pricing trajectories in the United States of disease-modifying therapies (DMT) for multiple sclerosis (MS) over the last 20 years and assess the influences on rising prices.
Methods: We estimated the trend in annual drug costs for 9 DMTs using published drug pricing data from 1993 to...
Full Text:
page 9
2
Investigators
Daniel M. Hartung, PharmD, MPH1*;
Dennis N. Bourdette, MD
Background: Academic medical centers are examining relationships with the pharmaceutical industry
and making changes to limit interactions. Most doctors, however, practice outside of academic institutions
and see pharmaceutical detailers and accept drug samples and gifts. Little guidance for practicing
physicians exists about transforming practices to become pharma-free. Consideration must be...
PURPOSE: In February 2010, the US Food and Drug Administration (FDA) issued new recommendations for the safe use of long-acting beta agonists (LABA) in those with asthma.
The objective of this study was to determine the impact of the FDA’s 2010 LABA advisory on LABA utilization.
METHODS: Using administrative data...
Full Text:
FDA’s 2010 Drug
Safety Communication
Hartung, D. M., Middleton, L., Markwardt, S., Williamson, K
Objective: To examine the pricing trajectories in the United States of disease-modifying therapies (DMT) for multiple sclerosis (MS) over the last 20 years and assess the influences on rising prices.
Methods: We estimated the trend in annual drug costs for 9 DMTs using published drug pricing data from 1993 to...
PURPOSE: In February 2010, the US Food and Drug Administration (FDA) issued new recommendations for the safe use of long-acting beta agonists (LABA) in those with asthma.
The objective of this study was to determine the impact of the FDA’s 2010 LABA advisory on LABA utilization.
METHODS: Using administrative data...
PURPOSE: In February 2010, the US Food and Drug Administration (FDA) issued new recommendations for the safe use of long-acting beta agonists (LABA) in those with asthma.
The objective of this study was to determine the impact of the FDA’s 2010 LABA advisory on LABA utilization.
METHODS: Using administrative data...
PURPOSE: In February 2010, the US Food and Drug Administration (FDA) issued new recommendations for the safe use of long-acting beta agonists (LABA) in those with asthma.
The objective of this study was to determine the impact of the FDA’s 2010 LABA advisory on LABA utilization.
METHODS: Using administrative data...
PURPOSE: In February 2010, the US Food and Drug Administration (FDA) issued new recommendations for the safe use of long-acting beta agonists (LABA) in those with asthma.
The objective of this study was to determine the impact of the FDA’s 2010 LABA advisory on LABA utilization.
METHODS: Using administrative data...
PURPOSE: In February 2010, the US Food and Drug Administration (FDA) issued new recommendations for the safe use of long-acting beta agonists (LABA) in those with asthma. The objective of this study was to determine the impact of the FDA’s 2010 LABA advisory on LABA utilization. METHODS: Using administrative data...
Background: Academic detailing is an interactive, convenient, and user-friendly approach to delivering non-commercial education to healthcare clinicians. While evidence suggests academic detailing is associated with improvements in prescribing behavior, uncertainty exists about generalizability and scalability in diverse settings. Our study evaluates different models of delivering academic detailing in a rural...
Through improved adherence, once-monthly injectable extended-release naltrexone (XR-NTX)
may provide an advantage over other oral agents approved for alcohol and opioid dependence
treatment. The objective of this study was to evaluate cost and utilization outcomes between
XR-NTX and other pharmacotherapies for treatment of alcohol and opioid dependence.
Published studies were...
BACKGROUND: Result summaries are now required to be reported in ClinicalTrials.gov for many 1 trials of drugs and
devices.
PURPOSE: To evaluate the consistency of reporting in trials that are both registered in the ClinicalTrials.gov results
database and published in the literature.
DATA SOURCES: ClinicalTrials.gov results database, matched publications identified...
Full Text:
:
*DanielHartung, PharmD, MPH
1
, Deborah A. Zarin, MD
2
, Jeanne-Marie Guise, MD, MPH
3
, Marian
The pigeon guillemot (Cepphus columba) population in Prince William Sound has failed to recover from declines that occurred both before and after the Exxon Valdez Oil Spill (EVOS). Post-spill studies of pigeon guillemot breeding biology have identified three potential factors limiting recovery: (1) predation on eggs and nestlings; (2) declines...
I investigated the relationship between harlequin duck (Histrionicus histrionicus) behavior and lack of recovery from the Exxon Valdez oil spill in Prince William Sound, Alaska. First, I evaluated the hypothesis that harlequin ducks in winter have little flexibility to increase foraging time in response to disturbance because they are constrained...
The 1989 Exxon Valdez oil spill was a major perturbation of nearshore habitats of Prince William Sound, a wintering area for harlequin ducks (Histrionicus histrionicus). This research was designed to evaluate harlequin duck population recovery from the oil spill from 1995 to 1998, using a demographic approach to assess both...
The Arctic climate system is changing dramatically as a response to rising atmospheric greenhouse gas concentrations. Key indicators of Arctic change include thinning and retreating of Arctic pack ice, thawing permafrost, greening tundra, and rising surface temperatures. The structure of the atmospheric boundary layer influences and is influenced by processes...